NIDCD Core for Clinical Research and Care

NIDCD 临床研究和护理核心

• 批准号: 10688975
• 负责人: Clint Allen
• 金额: $ 279.85万
• 依托单位: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10688975
• 关键词: AQP1 gene; Adjuvant Study; Administrator; Admission activity; Adult; Affect; Ambulatory Care Facilities; Appointment; Area; Audiology; Care given by nurses; Caring; Child; Chromosome Mapping; Cisplatin; Clinical; Clinical Clerkship; Clinical Data; Clinical Investigator; Clinical Research; Clinical Services; Clinical Trials; Clinics and Hospitals; Communication; Communication impairment; Complex; Consult; Consultations; Continuing Education; Credentialing; Data; Data Collection; Databases; Development; Disease; Dose; Drug Kinetics; Emergency Situation; Endoscopy; Equilibrium; Equipment and Supplies; Evaluation; Fellowship; Fostering; Genes; Genetic study; Genomics; Head Cancer; Head and Neck Cancer; Head and Neck Disorder; Head and Neck Squamous Cell Carcinoma; Head and Neck Surgeon; Hearing; Hearing problem; Hereditary Disease; Hospital Administration; Hospitals; Hour; Human; Human Papilloma Virus Vaccine; Human Papillomavirus; Human Resources; Human papilloma virus infection; Image; Immune; India; Inpatients; Institutes; Institutional Review Boards; Intervention Studies; Intramural Research Program; Laboratories; Labyrinth; Maintenance; Malignant Neoplasms; Medical; Medical Students; Mentors; Mission; Molecular; Molecular Analysis; Monitor; NF-kappa B; National Institute on Deafness and Other Communication Disorders; Natural History; Neck Cancer; Nurse Practitioners; Nursing Research; Olfactory Neuroblastoma; Operative Surgical Procedures; Otolaryngologist; Otolaryngology; Outpatients; Pakistan; Parotid Gland; Pathogenesis; Patient Care; Patient Education; Patients; Phase; Phase I/II Trial; Phenotype; Physicians; Program Development; Proteomics; Protocols documentation; Provider; Records; Recurrence; Recurrent respiratory papillomatosis; Research; Research Support; Research Training; Resectable; Resources; Safety; Salivary; Scientist; Services; Signal Transduction; Solid Neoplasm; Specimen; Speech; Supervision; Surgeon; Syndrome; Testing; Time; Training; Transforming Growth Factor beta; Travel; Triad Acrylic Resin; United States National Institutes of Health; Vaccines; Vestibular Aqueduct; Visit; Voice; Work; adeno-associated viral vector; anti-PD-L1; anti-tumor immune response; atorvastatin; career development; chemotherapy; cisplatin induced hearing loss; clinical care; clinical implementation; data management; genetic analysis; genetic deafness; genome editing; hearing impairment; hearing restoration; hereditary hearing loss; human subject; inpatient service; irradiation; meetings; neoplasm therapy; outpatient programs; patient screening; phase 2 study; programs; protocol development; quality assurance; recruit; response; symposium; transcription factor; volunteer

The NIDCD Core for Clinical Research and Care supports the following NIDCD projects: 1 Z01-DC-000016 NF-kappaB in the molecular pathogenesis and therapy of Neoplasms Affecting Human Communication 1 ZIA DC000039 Identification of Genes Causing Syndromic And Nonsyndromic Hearing Impairment 1 ZIA DC000046 Genetic Studies of Human Communications Disorders 1 ZIA DC000060 Molecular Analysis Of Human Hereditary Deafness 1 ZIA DC000064 Clinical Analysis Of Disorders Of Hearing And Balance 1 ZIA-DC-000073 Signal and Transcription Factor Network Interactions in Head and Neck Cancer 1 ZIA-DC-000074 Genomics and Proteomics of Head and Neck Cancer 1 ZIA-DC-000082 Neurotology Program 1 ZIA-DC-000087 Characterization & Enhancement of Anti-tumor Immune Responses in Head & Neck Cancer 1-ZIA-DC-000088 Cellular and Molecular Pathogenesis of Hearing Restoration in Adullt Inner Ear 1-ZIA-DC-000090 Mechanisms and Optimal Combination of Cisplatin Chemotherapy for Head and Neck Cancer The NIDCD and collaborative protocols supported by the core include: OH93-DC-0016 - Nonsyndromic Hereditary Hearing Impairment Gene Mapping: India / Pakistan Protocol 97-DC-0180 - Genetic Analysis of Human Hereditary Hearing Impairment 01-DC-0228 - Clinical and Molecular Analysis of Hearing Impairment with Enlarged Vestibular Aqueducts 01-DC-0229- Genetic Analysis of Hereditary Disorders of Hearing and Balance 12-DC-0152 - Normative values in audiovestibular testing 17-DC-0138 - Cisplatin and statins in ototoxcity 18-DC-0051 - NIDCD Biospecimens protocol 20-DC-0047 - Natural History and Genome Editing in Dominant Hearing Loss 21-DC-0002- Phase III Interventional Study using Atorvastatin to Reduce Cisplatin-Induced Hearing Loss 21-C-0009 - A Natural History Study of Children and Adults With Olfactory Neuroblastoma 000077 Clinical Data and Specimens in head and neck disorders 000141 Hearing Instability Phenotyping 15-D-0129 Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 in Irradiation-Induced Parotid Salivary Hypofunction 19-C-0041 Birinapant and Intensity Modulated Re-Irradiation Therapy (IMRRT) for Locoregionally Recurrent Head and Neck Squamous Cell Carcinoma 19-C-0002 A Phase II Study of M7824 in Subjects with Recurrent Respiratory Papillomatosis 20-C-0024 Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination with TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated with Human Papillomavirus Infection 20-C-0155 Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetic , Immune and Clinical Activity of SX-682 in Combination with M7824 With CV301 TRICOM in Advanced Solid Tumors 20-C-0104 Phase I/II Trial of HPV Vaccine PRGN-2009 Alone or in Combination with Anti-PD-L1/TGF-Beta Trap (M7824) in Subjects with HPV Positive Cancers 21-C-0013 A Phase I/II Study of Adjuvant PRGN-2012 in Adult Patients with Recurrent Respiratory Papillomatosis The NIDCD Core for Clinical Research and Care supports over 3,000 outpatient clinic evaluations per year. Core otolaryngologists perform 50-100 major surgical cases annually. Staff mentor medical students during senior clinical clerkships. The Otolaryngologist Surgeon Scientist Career Development Program is coordinated through the OCD.

NIDCD临床研究和护理核心支持以下NIDCD项目： 1 Z01-DC-000016 NF-kappaB在影响人类交流的神经系统疾病的分子发病机制和治疗中的作用 1 ZIA DC000039综合征型和非综合征型听力障碍基因的鉴定 1 ZIA DC000046人类交流障碍的遗传学研究 1 ZIA DC000060人类遗传性耳聋分子分析 1 ZIA DC000064听力和平衡障碍的临床分析 1 ZIA-DC-000073头颈癌中的信号和转录因子网络相互作用 1 ZIA-DC-000074头颈癌基因组学和蛋白质组学 1 ZIA-DC-000082神经耳科项目 1 ZIA-DC-000087头颈癌中抗肿瘤免疫应答的表征和增强 1-ZIA-DC-000088成人内耳听力恢复的细胞和分子发病机制 1-ZIA-DC-000090顺铂化疗治疗头颈癌的机制及最佳组合 核心支持的NIDCD和协作协议包括： OH93-DC-0016-非综合征型遗传性听力障碍基因定位：印度/巴基斯坦方案 97-DC-0180-人类遗传性听力障碍的遗传分析 01-DC-0228-前庭水管扩大性听力损害的临床和分子分析 01-DC-0229-遗传性听力和平衡障碍的遗传分析 12-DC-0152-听觉前庭测试的标准值 17-DC-0138-顺铂和他汀类药物治疗耳毒性 18-DC-0051-NIDCD生物标本方案 20-DC-0047-显性听力损失的自然史和基因组编辑 21-DC-0002-使用阿托伐他汀减少顺铂诱导的听力损失的III期干预研究 21-C-0009-儿童和成人嗅神经母细胞瘤的自然史研究 000077头颈部疾病的临床数据和标本 000141听力不稳定表型 15-D-0129剂量递增研究，评价编码人水通道蛋白-1的腺相关病毒载体单次给药治疗辐射诱导的腮腺唾液功能减退症的安全性 19-C-0041 Birinapant和调强再放疗（IMRRT）治疗局部复发性头颈部鳞状细胞癌 19-C-0002一项在复发性呼吸道乳头状瘤病受试者中开展的M7824 II期研究 20-C-0024抗PD-L1/TGF-β Trap（M7824）单药治疗和与TriAd疫苗和N-803联合治疗与人乳头瘤病毒感染无关的可切除头颈部鳞状细胞癌 20-C-0155研究SX-682联合M7824和CV301 TRICOM治疗晚期实体瘤的安全性、耐受性、药代动力学、免疫和临床活性的I/II期试验 20-C-0104在HPV阳性癌症受试者中进行的HPV疫苗PRGN-2009单用或与抗PD-L1/TGF-β陷阱（M7824）联合治疗的I/II期试验 21-C-0013一项PRGN-2012辅助治疗复发性呼吸道乳头状瘤病成人患者的I/II期研究 NIDCD临床研究和护理核心每年支持3 000多个门诊诊所评估。核心耳鼻喉科医生每年进行50 - 100例大手术。在高级临床实习期间，工作人员指导医学生。耳鼻喉科医生外科医生科学家职业发展计划通过OCD协调。